Analyst price targets are worthless.
Stick with the science when promoting a drug/company. Much more convincing.
"Degree of nuance" can also be stated as "data mining".
Works in this bull market.
"Were" is the key word.
TPIV, ABEO, TXNP, SGNX (1 day pump) all down significantly from the "jbem buy peaks".
Only AVXL holding up.
Tell me, does jbem still own all those stocks? How about you? My guess is no on both accounts.
So it appears to me that jbem is one of the many pump and dumpers that frequent these message boards.
Good for the followers who bought early and sold, bad for the chasers that bought near the top of the pump.
Que sera, sera.
All the stocks mentioned started trending downward well before the "massive" bio slaughter.
Being down 15.5% from recent highs (IBB) is a correction. Oil down over 50% is a massive haircut.
But, like I said good for the ones who got in early, bad for the chasers.
Finally, I maybe foolish but I can surely tell a who is a pumper and who's an investor. Guess which one you are?
PS: I still own AVXL. So thanks.
No PR about the trial being fully enrolled so Part A is still ongoing. Part B won't be completed until late next year (if extension is granted).
There you have it ladies and gentlemen.
The pump: "Big data release next Wednesday that was moved up two months. Big warrants outstanding at much higher the price, crazily undervalued, this has AVXL/TPIV written all over it!!!!"
and then the dump: " I bought GNSZ at 0.77 and sold half yesterday at 0.90 and the rest today at 0.85 when it was clear it was a sell the news event."
Just for clarification, she doesn't work at Anavex.
She works for a PR firm representing the company.
The money Anavex is paying him says he wants to be associated with Anavex.
That's all well and good, now give me the full enrollment PR I been waiting for.
Nice summary, however I really don't think the Elesclomol failure is in anyone's mind at this point.
It's all about Ganetespib.
Also, analysts' price targets are worthless. For years Roth has had an elevated price target, the stock has never even come remotely close to it.
Releasing full enrollment is standard operating procedure for biotechs and portends nothing about the results of the trial.